Huadong Pharmaceutical announced that Zhejiang Daoer Biotechnology Co., Ltd., a holding subsidiary of the company, recently received a notice from the China National Drug Administration that its application for clinical trials of DR10624 injectable drugs has been approved, and clinical trials can be carried out in China. The indication is to treat heart failure with mild reduction in ejection fraction in adults. DR10624 is a long-acting tri-specific agonist targeting FGF21R, GCGR, and GLP-1R. This approval is an important advance in the product development process and will further enhance the company's core competitiveness in the field of cardiovascular and endocrine therapy.

Huadong Pharmaceutical announced that Zhejiang Daoer Biotechnology Co., Ltd., a holding subsidiary of the company, recently received a notice from the China National Drug Administration that its application for clinical trials of DR10624 injectable drugs has been approved, and clinical trials can be carried out in China. The indication is to treat heart failure with mild reduction in ejection fraction in adults. DR10624 is a long-acting tri-specific agonist targeting FGF21R, GCGR, and GLP-1R. This approval is an important advance in the product development process and will further enhance the company's core competitiveness in the field of cardiovascular and endocrine therapy.